Bogle Investment Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Bogle Investment Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-30,550	Closed	-$2.61M	–	349
2018 Q3	$2.61M	Sell	30,550 -68,081	-69%	-$6.82M	0.19%	133
2018 Q2	$11.4M	Buy	98,631 +36,730	+59%	+$3.67M	0.83%	58
2018 Q1	$5.01M	Buy	+61,901	New	+$4.76M	0.38%	95
2017 Q4	–	Sell	-37,967	Closed	-$1.78M	–	304
2017 Q3	$1.78M	Buy	+37,967	New	+$1.53M	0.12%	169
2017 Q2	–	Sell	-12,510	Closed	-$385K	–	321
2017 Q1	$385K	Buy	+12,510	New	+$390K	0.03%	272
2016 Q4	–	Sell	-13,832	Closed	-$368K	–	350
2016 Q3	$368K	Buy	+13,832	New	+$321K	0.03%	318
2013 Q4	–	Sell	-53,863	Closed	-$1.23M	–	315
2013 Q3	$1.23M	Buy	+53,863	New	+$1.03M	0.13%	205

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Bogle Investment Management's ENTA Position: Q4 2018 in Review

Bogle Investment Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2018, closing a stake of 30,550 shares — an estimated $2.61M sold.

Bogle Investment Management first reported a position in ENTA in Q3 2013 and held it in 7 quarters. The position peaked at $11.4M in Q2 2018. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

Bogle Investment Management reported no remaining Enanta Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Bogle Investment Management sold 30,550 Enanta Pharmaceuticals shares in Q4 2018, an estimated $2.61M.
Bogle Investment Management first reported a position in Enanta Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Bogle Investment Management's Enanta Pharmaceuticals position peaked at $11.4M in Q2 2018.
183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on Bogle Investment Management's 13F filing for Q4 2018, filed 13 Feb 2019.